HF1269

Coverage of medical services and prescription medications for the treatment of dementia required, and step therapy requirements for medical assistance modified.
Legislative Session 94 (2025-2026)

Related bill: SF1998

AI Generated Summary

Purpose

  • Require health plan companies to cover all FDA-approved medical services and prescription medications used to treat or slow the progression of dementia.
  • Require coverage for diagnostic testing to determine whether a medical service or medication is appropriate or effective for treating or slowing dementia.
  • Prohibit the use of step therapy protocols when providing this dementia coverage.

Main Provisions

  • Coverage scope: Health plans must cover every FDA-approved medical service and prescription medication used to treat or slow dementia, as well as related diagnostic tests to assess appropriateness or effectiveness.
  • Step therapy ban: Health plans may not apply step therapy (a process that requires trying less expensive or fewer-risk options before more costly or newer treatments) for the dementia-related services and medications described.
  • Legal amendments: Makes changes to Minnesota Statutes, including amending section 256B.0625 subdivision 13f and adding new provisions in Minnesota Statutes chapter 62Q (specifically 62Q.546).

Significant Changes to Existing Law

  • Broadens required coverage for dementia care by mandating FDA-approved treatments and associated diagnostic testing.
  • Restricts the use of step therapy for dementia treatments, limiting insurers’ ability to delay or deny access to dementia therapies.
  • Introduces a new statutory provision (62Q.546) to codify these dementia coverage requirements and related protections.

Potential Impacts and Considerations

  • Access: Aims to reduce barriers to dementia treatment by ensuring comprehensive coverage and timely access to therapeutics and diagnostics.
  • Costs: May affect premium levels and insurer budgeting due to broader coverage requirements.
  • Scope: Applies to dementia treatments approved by the FDA; does not mention non-FDA-approved or experimental therapies.

Relevant Terms dementia, FDA-approved, medical services, prescription medications, diagnostic testing, coverage, health plan company, step therapy, step therapy protocol, 62Q.184 subdivision 1, 62Q.546, Minnesota Statutes, 256B.0625 subdivision 13f, medical assistance

Bill text versions

Showing the most recent version. There are  2  total versions. You must be logged in  to view additional bill text versions.

Actions

DateChamberWhereTypeNameCommittee Name
February 20, 2025HouseActionIntroduction and first reading, referred toCommerce Finance and Policy
February 24, 2025HouseActionAuthor added
February 26, 2025HouseActionAuthor added
March 05, 2025HouseActionAuthor added
March 06, 2025HouseActionAuthors added
Showing the 5  most recent stages. This bill has 13  stages in total. Log in to view all stages

Citations

You must be logged in  to view citations.

Progress through the legislative process

17%
In Committee

Sponsors

You must be logged in  to view sponsors.

Loading…